Purpose of Review: Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC. Recent Findings: Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual. Summary: Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment.
Bibliographical noteFunding Information:
Sanjal Desai declares that she has no conflict of interest. Chul Kim received one-time travel support from Caris Life Sciences to an advisory board meeting in 2017; is the site PI for the CANOPY-1 trial (NCT03631199), funded by Novartis; and has received research support from AstraZeneca for an investigator-initiated trial of durvalumab in patients with viral infection and NSCLC. Irina Veytsman declares that she has no conflict of interest.
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
- Stage III
- Tyrosine kinase inhibitor